Evidence map›Paper›PMID 33823907›Full record

Trial reportTrials2021

How 'place' matters for addressing the HIV epidemic: evidence from the HPTN 071 (PopART) cluster-randomised controlled trial in Zambia and South Africa.

Virginia Bond, Graeme Hoddinott, Lario Viljoen, Fredrick Ngwenya, Melvin Simuyaba, Bwalya Chiti, Rhoda Ndubani, Nozizwe Makola, Deborah Donnell, Ab Schaap and 10 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01900977 (Population Effects of Antiretroviral Therapy to Reduce HIV Transmission), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01900977 nacompletednot on this map

Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-randomized Trial of the Impact of a Combination Prevention Package on Population-level HIV Incidence in Zambia and South Africa

TypeinterventionalSponsorHIV Prevention Trials NetworkRan2014 to 2018Enrolled48,540ConditionsHIVArmsUniversal Testing with immediate ART, Universal Testing with ART eligibility according to National Guidelines, Standard of Care
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Virginia BondDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, WC1H 9SH, UK. Virginia.Bond@lshtm.ac.uk.ORCID http://orcid.org/0000-0002-6815-4239
Graeme HoddinottDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town, 8000, South Africa.
Lario ViljoenDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town, 8000, South Africa.
Fredrick NgwenyaZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Melvin SimuyabaZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Bwalya ChitiZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Rhoda NdubaniZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Nozizwe MakolaDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town, 8000, South Africa.
Deborah DonnellFred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA, 98109-1024, USA.
Ab SchaapZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Sian FloydDepartment of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, LSHTM, Keppel Street, London, WC17HT, UK.
James HargreavesCentre for Evaluation, Faculty of Public Health and Policy, LSHTM, Keppel Street, London, WC17HT, UK.
Kwame ShanaubeZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Sarah FidlerNational Institute for Health Research Biomedical Research Centre, Imperial College, South Kensington, London, SW7 2BU, UK.
Peter BockDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town, 8000, South Africa.
Helen AylesZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Richard HayesDepartment of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, LSHTM, Keppel Street, London, WC17HT, UK.
Musonda SimwingaZambart, School of Public Health, University of Zambia, Ridgeway Campus, P.O. Box 50697, Lusaka, Zambia.
Janet SeeleyDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, WC1H 9SH, UK.
HPTN071 (PopART) study team

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials NetworkU01AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DONNELL, DEBORAH J · 2006 to 2010
$28.8M
Bill and Melinda Gates Foundation 00Department for International Development 00Medical Research Council MR/R010161/1National Institute of Allergy and Infectious Diseases UMq-AI068617NIAID NIH HHS U01 AI068617NIAID NIH HHS UM1 AI068617U.S. President's Emergency Plan for AIDS Relief 00
6 · The paper itself

Abstract

backgroundIn a cluster-randomised trial (CRT) of combination HIV prevention (HPTN 071 (PopART)) in 12 Zambian communities and nine South African communities, carried out from 2012 to 2018, the intervention arm A that offered HIV treatment irrespective of CD4 count did not have a significant impact on population level HIV incidence. Intervention arm B, where HIV incidence was reduced by 30%, followed national guidelines that mid trial (2016) changed from starting HIV treatment according to a CD4 threshold of 500 to universal treatment. Using social science data on the 21 communities, we consider how place (community context) might have influenced the primary outcome result.

methodsA social science component documented longitudinally the context of trial communities. Data were collected through rapid qualitative assessment, interviews, group discussions and observations. There were a total of 1547 participants and 1127 observations. Using these data, literature and a series of qualitative analysis steps, we identified key community characteristics of relevance to HIV and triangulated these with HIV community level incidence.

resultsTwo interdependent social factors were relevant to communities' capability to manage HIV: stability/instability and responsiveness/resistance. Key components of stability were social cohesion; limited social change; a vibrant local economy; better health, education and recreational services; strong institutional presence; established middle-class residents; predictable mobility; and less poverty and crime. Key components of responsiveness were community leadership being open to change, stronger history of HIV initiatives, willingness to take up HIV services, less HIV-related stigma and a supported and enterprising youth population. There was a clear pattern of social factors across arms. Intervention arm A communities were notably more resistant and unstable. Intervention arm B communities were overall more responsive and stable.

conclusionsIn the specific case of the dissonant primary outcome results from the HPTN 071 (PopART) trial, the chance allocation of less stable, less responsive communities to arm A compared to arm B may explain some of the apparently smaller impact of the intervention in arm A. Stability and responsiveness appear to be two key social factors that may be relevant to secular trends in HIV incidence. We advocate for a systematic approach, using these factors as a framework, to community context in CRTs and monitoring HIV prevention efforts.

trial registrationClinicalTrials.gov NCT01900977 . Registered on July 17, 2013.

Indexed as

EpidemicsHIV InfectionsAdolescentHumansSocial StigmaSouth AfricaZambiaCommunitiesCommunity randomised trials (CRTs)Social contextSouthern AfricaStability

Identifiers

PMID33823907
PMCPMC8025534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.